Introduction
Ras proteins are small guanosine triphosphatases (GTPases) that act as molecular switches by cycling between inactive guanosine diphosphate (GDP)-bound state and active GTP-bound state. The classical model for Ras activation following extracellular stimulation is based on the recruitment, through the interaction with receptors and molecular adapters, of guanine nucleotide exchange factors (GEFs) to the plasma membrane, in which Ras is located, and transiently they induce the formation of Ras-GTP complexes that stimulate multiple intracellular pathways to regulate cell growth, mobility, proliferation and survival (Marshall, 1999) . Once Ras has performed its function, GTPase-activating proteins (GAPs) are also recruited to the plasma membrane to stimulate GTP hydrolysis and deactivate Ras proteins. Mutations of Ras that prevent efficient GTP hydrolysis and thus render the protein in a constitutively activated state are found in a large number of human tumors, such as replacement of Gly 12 to Val (G12V), which generates a Ras mutant insensitive to GAP-induced GTP-hydrolysis (Bos, 1989; Malumbres and Barbacid, 2003) . H-Ras, N-Ras, K-Ras4A and K-Ras4B are different members of the Ras family that exhibit structural similarities in regions involved in interactions with guanine nucleotide exchange factors, GAPs and effectors, resulting in considerable, but not complete overlap in their regulation and functionality (Umanoff et al., 1995; Johnson et al., 1997; Yan et al., 1998) .
Despite ubiquitous expression and similar affinities for regulators and effectors, Ras proteins have distinct biological properties due to differences in the hypervariable carboxyterminal region that control their plasma membrane and intracellular distribution. Their differential localization determines specific Ras signaling output, becoming more accessible to a specific set of effectors and regulators (Hancock, 2003; Prior et al., 2003; Matallanas et al., 2006; Omerovic et al., 2007) . Although we have only begun to dissect Ras isoformspecific signaling, it has been described that N-Ras is a major activator of the Raf-1/MEK/ERK cascade, whereas K-Ras is an important regulator of the PI3K/ AKT pathway (Hamilton et al., 2001; Liao et al., 2006) . There are also reports that H-Ras, as compared with K-Ras, preferentially stimulates PI3K activity (Yan et al., 1998) . And proteins, such as Galectin-1 and Galectin-3 have an important role to anchor Ras proteins to different plasma membrane microlocalizations, generating nanoclusters and regulating Ras segregation and function. Galectin-3 interacts with activated K-Ras through the hypervariable carboxyterminal region and stimulates KRas activity triggering a Ras signal that attenuates ERK, but not PI3K (Elad-Sfadia et al., 2002 .
Another important issue is the duration and amplitude of Ras signaling. The wide variety of responses elicited by the activation of a single Ras pathway has been shown to rely on the timing and strength of this activation (Marshall, 1995; Agell et al., 2002) . High and sustained activation of the Ras/Raf/MEK/ERK pathway induces cell-cycle arrest that can be linked to either senescence, apoptosis or differentiation, whereas transient activation followed by a lower and also sustained level of ERK activity is a common feature of cell proliferation in many systems; however, if the duration of activation is too short, a failure in cyclin D1 expression is observed and cells do not proliferate (Kahan et al., 1992; Qui and Green, 1992; Pumiglia and Decker, 1997; Roovers and Assoian, 2000) . Consequently, positive and negative feedback loops for finely regulating Ras activity are very important.
The Ca 2 þ -binding protein calmodulin (CaM), which acts as a second messenger in cellular signal transduction pathways and regulates cell proliferation (Klee and Vanaman, 1982; Veigl et al., 1982; Lu and Means, 1993; Schulman, 1993) , is one of the molecules involved in the modulation of Ras activity (Agell et al., 2002; Moreto et al., 2008) . We have shown that CaM inhibition specifically enhances K-Ras activation provided protein kinase C (PKC) is active. It is interesting that we have also demonstrated that K-Ras is a CaM-binding protein, although it is only able to bind CaM if it is GTP-bound and not phosphorylated at Ser181, suggesting an interplay between CaM binding to K-Ras, K-Ras phosphorylation and K-Ras activity (Villalonga et al., 2001 Lopez-Alcala et al., 2008) .
Although PKC-dependent Ras activation has been reported in T lymphocytes upon T-cell receptor activation (Downward et al., 1990) , it does not occur in fibroblasts unless CaM is inhibited . Ballester et al. suggested that K-Ras could be phosphorylated in exon 4B by PKC, but this phosphorylation affected neither the binding to GTP nor the intrinsic GTPase activity of the Ras protein (Ballester et al., 1987) . Recently, the relevance of K-Ras phosphorylation has been analyzed. It has been shown that phosphorylation induces a reversible translocation of oncogenic K-Ras from the plasma membrane to the endoplasmic reticulum, Golgi apparatus and mitochondria, in which it stimulates Bcl-XL -dependent apoptosis (Bivona et al., 2006) . Furthermore, other researchers using the oncogenic form of K-Ras have shown that the largest part of phosphorylated K-Ras was still localized at the plasma membrane and that phosphorylation inhibited the formation of K-Ras-GTP nanoclusters, prompting a reduction in Raf-1 plasma membrane recruitment . However, the effect of phosphorylation on non-oncogenic K-Ras was not determined in any of these studies.
The aim of our work is to analyze the relation between CaM, K-Ras phosphorylation and K-Ras function. We demonstrate that CaM inhibits K-Ras phosphorylation at Ser 181 and consequently modulates the functionality of both the wild type and the oncogenic form of this small GTPase.
Results

CaM inhibits PKC phosphorylation at Ser181 of K-Ras
We have previously shown that CaM inhibits in vitro phosphorylation of K-Ras by PKC . As CaM interacts with the hypervariable carboxyterminal region of K-Ras, we analyzed whether the phosphorylation site regulated by CaM was in this region. hemagglutinin (HA)-tagged K-Ras was mutated in the different possible phosphorylation sites of the hypervariable carboxyterminal region (Ser171, Ser181 and Thr183) to alanine, expressed in COS cells, immunoprecipitated and used as substrates for the catalytic subunit of PKC in the presence or absence of CaM and Ca 2 þ . As expected, phosphorylation was drastically reduced in the presence of CaM. Furthermore, in the absence of CaM, K-Ras phosphorylation could not be observed when Ser181 was mutated to Ala, indicating that this was the residue phosphorylated by PKC in vitro (Figure 1a ). To determine whether CaM could inhibit K-Ras phosphorylation also in vivo, NIH3T3 cells were cotransfected with HA-KRasG12V plus green fluorescent protein-CaM. The oncogenic form was used because K-Ras only binds to CaM in the GTP-bound form. After serum-starvation, cells were treated with phorbol 12-myristate 13-acetate (PMA), to activate PKC or with PMA plus W13, to inhibit CaM at the same time. Phosphorylation of K-Ras was only stimulated when CaM was inhibited (Figure 1b) , indicating that CaM prevents K-Ras phosphorylation in vivo. Moreover, K-Ras phosphorylation was stimulated in vivo in NIH3T3 cells, in the presence of FBS, but not when Ser181 was mutated to alanine, demonstrating that the presence of growth factors induces K-Ras phosphorylation at Ser181 (Figure 1c ). It is interesting that HA-KRasG12V, transiently expressed in HEK293 cells, was also phosphorylated in the presence of growth factors, but this modification was dramatically reduced when CaM was simultaneously overexpressed. Finally, HA-KRasG12VDKK, a mutant with two Lys of the polybasic domain deleted that exhibits a reduced affinity for CaM (Lopez-Alcala et al., 2008) , was still phosphorylated after CaM over-expression (Figure 1d ). Consequently, we can conclude that K-Ras is phosphorylated in vivo in the presence of growth factors, or upon PKC stimulation and that this phosphorylation is inhibited by CaM interaction.
Phosphorylation at Ser181 is essential for K-Ras activation by PMA treatment plus CaM inhibition We previously showed that CaM inhibition plus PMA treatment in serum-starved NIH3T3 cells induced activation of K-Ras, whereas individual treatment with PMA or W13 alone did not. We also demonstrated that this activation was dependent on PKC activity. To elucidate the mechanism involved in this activation of K-Ras, we analyzed whether phosphorylation of Ser181 was essential. As shown in Figure 2a , no significant differences were observed, in NIH3T3 cells, at least after 10 min of PDGF addition between wild-type K-Ras and K-RasS181A, but PMA treatment activated K-Ras only if CaM was inhibited and if Ser181 could be phosphorylated. In our previous work we also demonstrated that CaM inhibition is not sufficient to induce Ras activation (Villalonga et al., 2001 , indicating that PKC activity is also required. Consequently, phosphorylation of K-Ras is essential for its activation by PKC when CaM is inhibited. Moreover, in the present work we demonstrate that in vivo phosphorylation of HA-KRas was stimulated in the presence of PMA and W13, whereas phosphorylation did not occur when Ser181 was mutated to Ala, indicating that this residue is also the one phosphorylated in vivo (Figure 2b ). Although we could not discard that CaM could also be having other roles on K-Ras function, these results provide evidence that phosphorylation of non-oncogenic K-Ras positively modulates its activity and indicates that Ca 2 þ /CaM through the regulation of this phosphorylation could modulate K-Ras activity. To finally prove the hypothesis that CaM is binding to K-Ras in the absence of growth factors, to prevent K-Ras phosphorylation and activation, this interaction needed to be proved. As shown in Figure 2c , at 0% fetal calf serum (FCS) K-Ras coimmunoprecipitates with CaM, whereas the pseudo-phosphorylated mutant did not. Thus, in serum-starved cells, CaM would be able to bind to the basal levels of Ras-GTP generated, preventing its phosphorylation and activation.
Phosphorylation of K-Ras reduces its susceptibility to p120GAP activity, but does not affect affinity to Ras-binding-domain (RBD) or Raf-1 To determine the mechanism relating K-Ras activation and K-Ras phosphorylation, we first analyzed whether phosphorylation was directly increasing the binding of K-Ras to RBD or to Raf-1. When expressing oncogenic K-RasG12V (always GTP-loaded) or the mutants K-RasG12V-S181A or K-RasG12V-S181D no changes in the affinity to RBD were found (Figure 3a) . Furthermore, immunoprecipitation of HA-K-RasG12V with the different mutations at Ser181 and further incubation with a lysate of cells overexpressing myc-Raf-1 demonstrated that phosphorylation did not promote Raf-1 interaction (Figure 3b) . Discarded a direct effect of K-Ras phosphorylation on Raf-1 binding, we analyzed whether phosphorylation reduced susceptibility to GAP activity in vivo. We focussed on GAP activity because K-Ras/CaM interaction is GTP dependent and consequently, CaM could only directly regulate GTP-loaded K-Ras phoshorylation. To this aim, non-oncogenic K-Ras with the same mutations indicated above and green fluorescent protein-p120GAP or green fluorescent protein alone were co-expressed in fibroblasts. Activation of K-Ras after 5 min of EGF treatment was then analyzed. As shown in Figure 3c , although the overexpression of p120GAP reduced K-RasGTP levels independently of the residue in position 181, it exhibits a major effect on nonphosphorylable K-Ras (which was 50% more efficiently inactivated than wild-type K-Ras), suggesting that phosphorylation decreased the ability of this GAP to deactivate K-Ras. This observation is not exclusive of fibroblast as same results were also obtained in HEK293 cells (Supplementary Figure S1) . During orthophosphate incorporation 100 ng/ml of EGF was added.
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Non-phosphorylable K-Ras fails to produce normal growth-factor-induced activation kinetics It is well documented that, in response to growth factor stimulation, Ras undergoes a transient activation, the kinetics of which is growth-factor and cell-type dependent (Downward, 1996) . Furthermore, the physiological output of Ras signaling depends on the amplitude and timing of its activation. We previously showed that in NIH3T3 cells inhibition of CaM induced a more sustained activation of mitogen-activated protein kinase (MAPK) upon FCS addition (Bosch et al., 1998) . As shown in Figure 4a , W13 addition also induced a higher activation of endogenous K-Ras, whereas PKC inhibition, achieved with bisindolylmaleimide I treatment, had the opposite effect. Moreover, the double treatment with W13 plus bisindolylmaleimide I demonstrated that stronger K-Ras activation after CaM inhibition is dependent on PKC activity (data not shown). As we have described that CaM inhibition facilitates K-Ras phosphorylation, we now aimed to analyze whether the lack of K-Ras phosphorylation could affect K-Ras activation profile. NIH3T3 cells expressing EGF receptor (NIH3T3WT8 cells) were transfected with HA-K-RasWT and HA-K-RasS181A, and the activation of K-Ras at different times after EGF addition was analyzed ( Figure 4b ). No significant differences were found in the maximum activation levels of K-Ras (between 5 and 7 min after EGF addition), but, it is interesting that activation of the non-phosphorylable K-Ras was less sustained. The activity of K-RasS181A started to decrease earlier, and was significantly lower between 8 and 10 min after EGF addition compared with wild-type K-Ras, which maintains its maximum activity between 5 and 10 min ( Figure 4c ). These results indicate that CaM inhibition facilitates K-Ras phosphorylation by PKC and consequently, it allows a sustained activation of KRas, possibly owing to its increased insensibilization to GAP deactivation. Furthermore, activation of KRasS181D was higher than K-RasS181A at short times, 2 min after EGF stimulation (Supplementary Figure S2) indicating again that the regulation of this phosphorylation is important for a proper temporal activation profile of K-Ras. But, not significant differences were observed between K-RasWT and phosho-mimetic mutant at later time point.
Non-phosphorylable K-Ras fails to activate AKT at low growth factor concentration It has been reported that K-Ras À/À MEF cell lines do not efficiently activate AKT, whereas no differences were observed in phospho-MAPK compared with wild-type MEF cells (Liao et al., 2006) . We decided to transfect these knock-out cells with HA-K-Ras and HA-KRasS181A to analyze whether phosphorylation was required to stimulate PI3K/AKT pathway. Cells were serum starved for 12 h and activated during 5 min at different FCS concentrations and we could observed that although the expression of HA-K-Ras induced an important increase in phospho-AKT levels, HA-KRasS181A had a reduced effect (Figure 5b ). In addition, to completely prove that this effect was mediated by K-Ras phosphorylation, HA-K-Ras-transfected cells were pre-treated during 20 min with PKC inhibitor before FCS stimulation and although these cells were expressing K-Ras, they were unable to correctly induce AKT phosphorylation. As shown in Figure 5c , no significant differences on AKT activation were observed after the expression of HA-K-RasS181D and HA-KRas, indicating that under these conditions the proportion of phosphorylated K-Ras is high enough to saturate the pathway. No further MAPK phosphorylation was observed after expression of any of the K-Ras mutants (Supplementary Figure S3) , most probably indicating that the pathway was fully activated by H-Ras and NRas. We could not discard that this phosphorylation could also be exerting an effect on MAPK pathway, ) were serum starved for 24 h and then treated for 10 min with the indicated drugs. Cells lysates (500 ml) were processed for RBD-sepharose (RBD-Seph.) pulldown. All proteins bound to RBD-Seph. and an aliquot (30 ml) of cell lysate (input) were electrophoresed and then western blotting was performed using anti-HA antibodies. HA-K-Ras bound to RBD-Seph. corresponds to Ras-GTP loaded. (b) K-Ras is phosphorylated in vivo after PMA and W13 treatment at Ser181. Lysates of NIH3T3 cells transfected with HA-K-Ras and HA-KRasS181A after serum starvation and orthophosphate radiolabeling (À) were treated with PMA and W13 for 10 min, immunoprecipitated and electrophoresed. Autoradiography and Coomassie Blue staining are shown. (c) CaM binds to K-RasG12V in the absence of growth factors. After serum starvation, crosslinked lysates of NIH3T3 cells stably expressing HA-K-RasG12V or HA-K-RasG12V-S181D were immunoprecipitaded and interaction with CaM was determined.
Calmodulin inhibits K-Ras phosphorylation B Alvarez-Moya et al because K-Ras þ / þ and K-Ras À/À cell lines exhibit the same phospho-ERK1/2 levels under stimulation. With these results and the above presented data, we can conclude that under strong stimuli, the effect of K-Ras phosphorylation on K-Ras activity could be important to regulate the duration of the signal, but at low stimulation this phosphorylation becomes essential to achieve a complete K-Ras activation and signaling through the PI3K/AKT pathway, thereby demonstrating that phosphorylation regulates K-Ras activity under physiological conditions.
Physiological relevance of Ser181 phosphorylation on non-oncogenic K-Ras
To assess the functional significance of K-Ras phosphorylation in the regulation of cell proliferation, we tested the ability of K-Ras, K-RasS181A and K-RasS181D to drive proliferation of cells lacking all three endogenous Ras isoforms (Rasless MEFs). Rasless cells cease proliferation and can be used as a tool to study the impact of any gene of interest on this process (Drosten et al., 2010) . To this end, H-Ras ; RERTn ert/ert mouse embryonic fibroblasts were infected with retroviruses expressing K-Ras, K-RasS181A (non-phosphorylable mutant) and KRasS181D (pseudo-phosphorylated mutant), as well as with control viruses. To determine the impact of each mutant on proliferation, cells were seeded at low density in the absence or presence of 4-hydroxytamoxifen to activate the resident CreERT2 recombinase and excise the K-Ras lox/lox alleles, and plates were scored for colony formation. Thus in this model, growth depends exclusively on the ectopically expressed mutant. No difference in colony formation could be observed in 10% FBS, suggesting that under high serum concentrations phosphorylation of S181 is not relevant. However, when serum concentration was reduced to 5%, thus mimicking growth under less saturating conditions, colony formation in Rasless cells expressing K-Ras-S181A were significantly reduced (Figure 6a ). This 50% reduction observed when K-Ras cannot be phosphorylated was not due to the variation in the expression levels of the different K-Ras mutants (Figure 6b) . Hence, these data indicate that K-Ras phosphorylation is required to drive cell proliferation under less favorable conditions.
Phosphorylation also modulates oncogenic K-RasG12V functionality
We also wanted to analyze whether phosphorylation could modulate the functionality of oncogenic K-RasG12V, to assess whether this modification could regulate K-Ras interaction with other effectors different from p120GAP. As shown in Figure 7a , K-RasG12V-S181A had 30% reduced activity in a focus formation assay compared with K-RasG12V. Furthermore, when analyzing the mobility of cells transfected with the different K-Ras mutants we found that although K-RasG12V and K-RasG12V-S181D induced a significant increase in NIH3T3 cells mobility, this increase was not observed when cells were transfected with the nonphosphorylable oncogenic K-Ras mutant (Figure 7b ). We also wanted to investigate how oncogenic K-Ras phosphorylation affected cell survival. To this aim, NIH3T3 cell lines stably expressing the different phosphorylation K-Ras mutants, were treated with adriamycin, a pro-apoptotic drug. As shown in Figures  8a and b , although K-RasG12V and K-RasG12V-S181D expression rendered NIH3T3 cells resistance to adriamycin treatment, K-RasG12V-S181A did not. This was analyzed by caspase-3 and PARP cleavage and by directly measurement of cell survival by crystal violet staining. Finally, survival after serum deprivation was analyzed. NIH3T3-stable cell lines were seeded at 0.1% FCS, and their ability to survive under these . Cells were harvested at the indicated times and the amount of endogenous K-Ras-GTP loaded analyzed by RBD pull-down followed by western blotting using anti-K-Ras antibodies. (b) NIH3T3WT8 cells transfected with either HA-K-Ras or HA-K-RasS181A were serum starved and then EGF added. At the indicated times cells were harvested and processed for RBD -pull-down followed by western blotting using anti-HA antibodies to determine the amount of HA-K-Ras-GTP loaded. An aliquot of cell lysate (input) was also processed for western blotting to compare HA-K-Ras expression levels. A representative experiment is shown. (c) Graph representing the quantification of six different experiments is shown. Western blot signals were quantified, corrected by HA-K-Ras expression levels and referred to 5 min value of HA-K-Ras. Error bars indicate±s.d.m.; *Po0.05; **Po0.01; n ¼ 6 for all times except for 8.5 min where n ¼ 3.
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B Alvarez-Moya et al conditions was monitored. As shown in Figure 8c , at low growth factors concentration K-RasG12V and KRasG12V-S181D, initially supported proliferation, but eventually, they reached crisis, and cell number started dropping. In contrast, in stable cell lines expressing KRasG12V-S181A and NIH3T3 control cells, viable cell numbers dropped from the beginning. Consequently, impeding or blocking oncogenic K-Ras phosphorylation, K-Ras exhibits a reduced capability to stimulate cell survival at low growth factor concentration. Lack of effect of K-RasG12V-S181D in relation to K-RasG12V may indicate that, under the analyzed conditions, the proportion of K-RasG12V being phosphorylated is high enough to induce a complete activation of the different signaling pathways.
Non-phosphorylable K-Ras fails to activate AKT and MAPK at low growth factor concentration As K-RasG12V-S181A could not support proliferation and survival at low growth factor concentration, we investigated the downstream signaling of oncogenic KRas under these conditions. As shown in Figure 8d , in the presence of 10% FCS, AKT and MAPK phosphorylation was observed in all cell lines, but, when cells were maintained at 0.1% FCS for 2 days, activation of both signaling pathways was clearly decreased in cells expressing K-RasG12V-S181A, indicating that phosphorylation of oncogenic K-Ras is important to allow its downstream signaling at low growth factor doses. Discrepancy between the similar in vitro affinity of K-RasS181D and K-RasS181A to RBD and Raf1 (Figures 3a and b ) and the differences in the in vivo activation of the MAPK pathway observed at low growth factor concentrations, could be explained by different membrane microdomain localization in function of the phosphorylation status of K-Ras.
Discussion
During the last years phosphorylation of K-Ras has appeared as a possible mechanism to modulate the activity of the oncogenic form of this GTPase, but functionality of this phosphorylation is controversial. Although some authors showed that it induced a massive internalization of K-RasG12V to stimulate cellular apoptosis (Bivona et al., 2006) , other researchers observed that phosphorylated K-RasG12V was mainly located at the plasma membrane (Lopez-Alcala et al., 2008) and favored PC12 cell differentiation . In the present work we describe that K-Ras is phosphorylated at Ser181 by PKC, in fibroblasts and HEK293 cells, after growth factor addition and we demonstrate the relevance of this phosphorylation in non-oncogenic and oncogenic K-Ras signaling. Moreover, CaM inhibits this phosphorylation in vivo and in consequence modulates K-Ras functionality. The fact that CaM inhibits K-Ras phosphorylation is not surprising as Ser181 is found within one of the CaMbinding domains of K-Ras, and probably CaM can hide the phosphorylation site. This regulatory mechanism has already been shown for other CaM-binding proteins, such as neurogranin, neuromodulin, myristylated alanine-rich C-kinase substrate (Chakravarthy et al., 1999) and p21 (Rodriguez-Vilarrupla et al., 2005; Agell et al., 2006) . In analogy to other CaM-binding proteins, phosphorylation within the CaM-binding region of K-Ras inhibits its binding to CaM (Lopez-Alcala et al., 2008) . Thus, also for K-Ras, there is an antagonism between CaM and PKC: CaM inhibits phosphorylation by PKC and phosphorylation inhibits binding of CaM.
We previously showed that CaM was preventing K-Ras activation by PKC in fibroblasts, thus, simultaneous CaM inhibition and PKC activation was inducing K-Ras activity . Now we found that this activation is dependent on Ser181 K-Ras phosphorylation. But this result does not exclude the Calmodulin inhibits K-Ras phosphorylation B Alvarez-Moya et al possibility that CaM could also be acting at some other level in the K-Ras activation pathway. From our work, we can also conclude that most probably K-Ras-GDP cannot be phosphorylated by PKC, because CaM is inhibiting K-Ras phosphorylation and only binds to GTP-loaded K-Ras. In fact our unpublished results indicate that K-RasN17 cannot be phosphorylated, maybe other proteins could be inhibiting K-Ras-GDP phosphorylation, or this K-Ras conformation has a reduced affinity for PKC.
As CaM was inhibiting K-Ras phosphorylation and activation, we investigated the relevance of this posttraductional modification on the activation of nononcogenic K-Ras. It has been shown that K-Ras physiological output depends on its activation profile (Marshall, 1995) , and in agreement with our previous work showing that CaM inhibition allowed a more sustained growth-factors activation of the MAPK pathway, in this study we demonstrate that K-Ras activation was also more prolonged upon CaM inhibition. Moreover, PKC inhibition decreased K-Ras activation in fibroblasts, and CaM inhibition could not enhance K-Ras activation if PKC was inhibited. And this is in fact due to the lack of K-Ras phosphorylation, as non-phosphorylable K-Ras also exhibits less sustained activation kinetics.
K-Ras/CaM interaction is GTP-dependent, and for that reason we envisage that CaM release from K-Ras should occur after growth factors K-Ras activation, to facilitate its phosphorylation by PKC and to allow a more prolonged activation. Moreover, by re-introducing either K-Ras or K-RasS181A into K-Ras À/À cells, we also showed that non-phosphorylable K-Ras was unable to activate AKT at low growth factor concentration.
In addition, we describe for the first time the physiological relevance of non-oncogenic K-Ras phosphorylation, showing that it is essential to rescue cell proliferation specifically under less favorable conditions. It is possible that lack of proliferation obtained with cells expressing only K-RasS181A could be due to a lower AKT activation, to a shorter K-Ras activation profile or both at the same time.
Phosphorylation could be important to prevent its inactivation by GAP, and we report in this study that non-phosphorylable K-Ras is more susceptible to GAP activity. But this is not the only effect of K-Ras phosphorylation as we also show that it can modulate oncogenic K-Ras cellular responses. Our results strongly suggest that phosphorylation of K-RasG12V is important to stimulate transformation, mobility, apoptosis resistance upon adriamycin treatment and to favor proliferation and survival at low growth factor concen- Calmodulin inhibits K-Ras phosphorylation B Alvarez-Moya et al tration. Our data agree with the fact that in some tumor cell lines, such as MIA-PaCa2 or HCT116, PKC activity stimulates cell survival and proliferation provided that K-RaG12V is expressed (Liou et al., 2004) or with some other reports in which it was demonstrated that PKC functions as a critical anti-apoptotic signal transducer in cells containing activated K-Ras, promoting cell survival through PI3K/PDK1/AKT pathway (Xia et al., 2007 (Xia et al., , 2009 . In contrast to previously published data (Bivona et al., 2006) , phospho-mimetic K-Ras expression did not induce apoptosis in our cell lines. Different expression levels of K-Ras or pro-apoptotic proteins, in the used cell lines, could explain these opposed results. Finally, and complementing the previous data, nonphosphorylable K-RasG12V-S181A has a compromised ability to activate MAPK and AKT at low growth factor concentrations, when compared with phosphorylable K-RasG12V. Thus, we demonstrate that downstream signaling of both non-oncogenic and oncogenic K-Ras is compromised at low growth factor conditions if K-Ras cannot be phosphorylated. As phosphorylation favors oncogenicity of K-RasG12V and CaM is preventing this phosphorylation, another conclusion of our results is that CaM binding to K-Ras would have tumor suppressor activity. Thus, to inhibit K-Ras phosphorylation or mimic CaM binding could be a good strategy to improve anti-tumoral therapy. In fact, PKC inhibition has been shown to reduce oncogenic KRas induced tumor growth in vivo and in nude mouse xenograft models (Liou et al., 2004) .
Given the presented results and our previously published data showing that CaM colocalized with K-Ras mainly at the plasma membrane and that phosphorylated K-Ras was also mainly located at the plasma membrane, we hypothesize that CaM interaction and K-Ras phosphorylation modulate localization of both oncogenic and non-oncogenic K-Ras in different discrete plasma membrane microdomains (Figure 9 ). Compartmentalization of K-Ras in microdomains, from which it can generate different signaling responses, is emerging as an important mechanism to regulate Ras signaling. The mechanisms underlying this compart- Calmodulin inhibits K-Ras phosphorylation B Alvarez-Moya et al mentalization involve a series of protein-lipid, lipidlipid and cytoskeleton interactions. We propose that CaM could have a similar function as galectin-3 (Ashery et al., 2006; Shalom-Feuerstein et al., 2008) promoting the formation of K-Ras microdomains, but in these CaM-enriched microdomains K-Ras phosphorylation by PKC would be inhibited. When Ca 2 þ decreases, CaM will release K-Ras and phosphorylation would be permitted inducing an electrostatic switch leading to K-Ras relocalization to a different microdomain. Microdomains of non-phosphorylated K-Ras would be more accessible to p120GAP leading to a less sustained signaling, whereas the ones of phosphorylated K-Ras could be enriched with other specific effectors, explaining how CaM and phosphorylation would modulate non-oncogenic and oncogenic K-Ras functionality. CaM, K-Ras phosphorylation and other elements may affect localization of K-Ras in such microdomains after growth factor addition, having a major effect under non-saturating stimulation.
Materials and methods
Cell culture, plasmids and transfection NIH3T3 cells and NIH3T3WT8 cells that stably overexpress the EGF receptor (a gift from Dr A Sorkin, University of Colorado, USA) were grown in Dulbecco's minimum essential medium (DMEM) supplemented with 10% donor calf s erum. Wild-type MEFs, K-Ras knock-out MEFs K-Ras À/À , (a gift from Dr M Barbacid, CNIO, Madrid, Spain) HEK293 and COS-1 cells were grown in DMEM supplemented with 10% FCS. Transient expression of the different K-Ras mutants in NIH3T3, NIH3T3WT8, KEK293 and COS-1 cells was achieved by transfecting cells with the appropriate expression vector using Lipofectamine (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. Stable transformants of NIH3T3 were generated by co-transfection with 100 ng pCDNA3.1 (to provide neomycin resistance) and 2 mg pEFHA-K-Ras with the respective oncogenic Ras mutant (HA-K-RasG12V, HA-K-RasG12V-S181A or HA-KRasG12V-S181D) and they were selected with G418 for 15 days. H-Ras ; RERTn ert/ert mouse embryonic fibroblasts (Drosten et al., 2010) were infected with empty pBABEpuro or pBABEpuro-expressing K-Ras WT, KRasS181A and K-RasS181D. Equal cell numbers were seeded at low density in the absence and presence of 600 nM 4-hydroxytamoxifen (to eliminate endogenous K-Ras by activation of the resident CreERT2 recombinase). Colony formation was scored after 14 days by crystal violet staining. Experiments were performed in triplicate at 10 and 5% FCS. pEFHA-K-Ras plasmid was a gift from R Marais (UK Cancer Research Centre, London, England). Mutants were obtained by single PCR, but with reverse or forward oligonucleotides carrying the appropriate mutations. For further subcloning in pEFHA or pYFP the forward oligonucleotide incorporated a BamHI or BglII site and the reverse one a ClaI or Sal I site, respectively.
Drugs and antibodies PDGF and EGF were used at a final concentration of 10 ng/ml and 100 ng/ml, respectively, PMA at 100 nM bisindolylmaleimide I at 5 mM, W13 at 15 mg/ml and adriamycin at 5 mM. The following antibodies were used for western blotting: pan-Ras (Oncogene Science OP40, 1:100 dilution), anti-HA (Roche 1583816, clone 12CA5 1:1000 dilution), K-Ras (Santa Cruz Biotechnology, Santa Cruz, CA, USA, (F234):sc-30, 1:500 dilution), RasGAP (Santa Cruz Biotechnology, (B4F8):sc-63, 1:500 dilution), c-Myc (Santa Cruz Biotechnology, (A-14):sc-789, 1:1000 dilution) and phospho-ERK1/2 (Cell Signaling, Danvers, MA, USA, #9101, 1:100), MAPK (Cell Signaling, #9102, 1:1000), AKT (Cell Signaling, #9272, 1:1000) all these incubations were performed for 1 h at room temperature. Phosphor-AKT-Ser473 (Cell Signaling, #9271, 1:1000), Phosphor-AKT-Thr308 (Cell Signaling, #9275, 1:1000), cleaved caspase-3 (Cell Signaling, #9661, 1:1000), cleaved PARP (Cell Signaling, #9548, 1:1000) and anti-calmodulin (Upstate #05-173, 1:1000) were incubated overnight at 4 1C.
In vitro phosphorylation COS-1 cells were cultured in 100-mm 2 plates and transfected with appropriated HA-K-Ras mutants and 24 h after transfection, cells were washed in phosphate-buffered saline and lyzed with Ras extraction buffer (20 mM Tris-HCl, pH 7.5, 2 mM EDTA, 100 mM NaCl, 5 mM MgCl 2 , 1% (v/v) Triton X-100, 5 mM NaF, 10% (v/v) glycerol and 0.5% (v/v) 2-mercaptoethanol) supplemented with a cocktail of protease and phosphatase inhibitors (0.1 mM Na 3 VO 4 , 1 mM phenylmethyl- Figure 9 Illustration of the speculative model proposed for the regulation of K-Ras functionality by PKC phosphorylation. Upon K-Ras activation, CaM and Ser181 phosphorylation can regulate K-Ras plasma membrane microlocalization. Interaction with Ca 2 þ / CaM hides Ser181 inhibiting its phosphorylation by PKC and non-phosphorylated K-Ras would be located in membrane microdomains with high levels of GAP, inducing a short and low signaling of K-Ras. When Ca 2 þ levels decrease or CaM is inhibited, phosphorylation of K-Ras is allowed. Phosphorylated K-Ras could be redirected to different membrane microdomains with lower levels of GAP and high levels of effectors where it would be able to completely induce proliferation and survival, This effect of K-Ras phosphorylation is mainly observed at low growth factor concentration because at higher doses, stimulation of other pathways might collaborate to translocate K-Ras to these effectors enriched microdomains. A full colour version of this figure is available at the Oncogene journal online.
Calmodulin inhibits K-Ras phosphorylation B Alvarez-Moya et al sulfonyl fluoride, 10 mM b-glycerophosphate, 2 mg/ml aprotinin and 10 mg/ml leupeptin). Total cellular lysates were immunoprecipitated with 30 ml of anti-HA agarose beads (SigmaAldrich, St Louis, MO, USA) 2 h at 4 1C. After three washes with Ras extraction buffer and one wash with kinase buffer (25 mM Hepes pH 7.5 and 10 mM MgCl 2 ) the immunoprecipitated Ras was incubated with a mixture containing 25 mM Hepes, pH 7.5, 10 mM MgCl 2 , 2 mM dithiothreitol, 4 mM CaCl 2 and 100 mM adenosine triphosphate in the presence or absence of CaM (7 mg) in a final volume of 40 ml. The reaction was initiated by adding 0.25 ml of rat brain PKC catalytic fragment (Biomol, Plymouth Meeting, PA, USA) and 2 mCi (g-32 P) adenosine triphosphate (3000 Ci/mmol) (Amersham Biosciences, Sunnyvale, CA, USA). Samples were incubated at 30 1C for 30 min, and the reaction was stopped by the addition of Laemmli sample buffer. Samples were electrophoresed on SDS-PAGE and the gel was stained with Coomassie Blue, destained and dried. The digital data were obtained with an Amersham Typhoon (Sunnyvale, CA, USA).
In vivo phosphorylation 100-mm 2 plates of NIH3T3 or HEK293 cells were transfected the indicated HA-K-Ras mutants or co-transfected with HA-K-RasG12V plus green fluorescent protein-CaM and serum starved for 24 h. After pre-incubating cells for 2 h with 4 ml of phosphate-free DMEM (Gibco, Invitrogen life technologies, Carlsbad, CA, USA), 2.5 mCi of orthophosphate radionuclide (Perkin Elmer, Waltham, MA, USA) was added and 1 h later cells were treated with PMA plus W13 for 10 min. Cells were washed in phosphate-buffered saline and lyzed with 500 ml Ras extraction buffer, and clarified lysates were then immunoprecipitated using 30 ml of anti-HA agarose beads. Samples were electrophoresed on SDS-PAGE and processed as indicated for in vitro phosphorylation.
Measurement of Ras activation
RBD (Ras-binding domain of Raf-1) pull downs were performed as previously described (Lopez-Alcala et al., 2008) to determine the amount of active Ras. , cultured on DMEM 5% donor calf serum and 15 days later they were fixed and stained with crystal violet, before scoring the foci.
Cell mobility analysis NIH3T3 cells were transfected with YFP-K-RasV12, YFP-KRasV12S181A and YFP-K-RasV12S181D and 3000 transfected cells were seeded onto four-chambered coverglass (Nalge Nunc, Rochester, NY, USA). After 12 h nuclei were stained with DRAQ5 (5 mM) for 10 min at 37 1C and images were acquired with a Leica TCS SP5 laser scanning confocal microscope, including an incubation system with temperature and CO 2 control. DRAQ5 and YFP were acquired at 5-min time interval over 12 h using Â 20 objective lens, 514-and 633-nm laser line, Acousto-Optical Beam Splitter, emission detection range of 525-600 and 650-745 nm, respectively, and the confocal pinhole was set at 2.5 Airy units. Differential interferences contrast images were also acquired. Image treatment and movie assembly were performed using the Image J Software (Wayne Rasband, National Institutes of Health). Mobility parameters, including migration path, distance traveled and directional persistence, were obtained from time-lapse movies with the plug-in Particle Analysis, MTrack2 (Nico Stuurman).
Measurement of proliferation and survival rates NIH3T3 cells and two different stable cell lines expressing the same amounts of HA-K-RasG12V, HA-K-RasG12V-S181A and HA-K-RasG12V-S181D were seeded at 2 Â 10 4 cells per p24 and serum starved (0.1% FCS) for different time points. Cells were fixed for 15 min in 4% paraformaldehyde, washed three times with phosphate-buffered saline and stained for 10 min with 0.25% crystal violet (Sigma-Aldrich) in water. Wells were washed, air-dried and solubilized in 0.2% Triton-X100. Optical density was measured at 590-nm wavelength with Synergy 2 Multi-Mode Microplate-Reader.
CaM Coimmunoprecipitation
150-mm
2 plates of NIH3T3 stable cell lines expressing HA-KRasG12V and HA-K-RasG12V-S181D were serum starved for 48 h, crosslinked with 5.5% formaldehyde (10 ml of DMEM plus 1.5 ml of formaldehyde 37% (Merck, Darmstadt, Germany)) during 10 min and the reaction was stopped by adding a solution containing 1 g of Glicine in 10 ml of TrisHCl pH8 (10% of the final volume) for 10 min. Cells were washed 5 times with cold phosphate-buffered saline, lyzed with Ras extraction buffer supplemented with a cocktail of protease and phosphatase inhibitors plus DNAase and incubated on ice for 1 h. After protein quantification 300 mg of protein were incubated with 30 ml of anti-HA agarose beads (SigmaAldrich) 2 h at 4 1C. Beads were washed three times with Ras extraction buffer and 30 ml of Laemmli sample buffer with
